The Board of Anagenics Limited announced the intention of Mr. Dennis Eck to retire as a director following the completion of the Company's 2022 Annual General Meeting. Mr. Eck made a strategic investment in the company in December 2017 and has been a Non- Executive Director at Anagenics since March 2018. Dennis has been supportive of the continuing restructuring and repositioning of the Business and expresses his intention to continue as a supportive shareholder.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.008 AUD | 0.00% | 0.00% | -57.89% |
May. 24 | Anagenics Signs Midkine Antibody Licencing Deal with Roquefort Therapeutics | MT |
Mar. 08 | Anagenics Appoints CEO | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-57.89% | 2.51M | |
+13.70% | 393B | |
+16.95% | 144B | |
+23.03% | 80.46B | |
-1.59% | 73.78B | |
-29.33% | 37.06B | |
-14.82% | 35.12B | |
+2.10% | 33.63B | |
+12.48% | 18.76B | |
+13.50% | 13.37B |
- Stock Market
- Equities
- AN1 Stock
- News Anagenics Limited
- Anagenics Limited Announces Resignation of Dennis Eck as Director